{"transactions":[{"id":4618412,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:07:01.000Z","date":"2026-09-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":1936,"price":156.22,"value":302441.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold."}],"balance_after":22647,"source":{"system":"sec-edgar","filing":"0001894425-26-000020","document":"wk-form4_1789506418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1894425/000189442526000020/wk-form4_1789506418.xml","form_type":"4"}},{"id":4618411,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-15T21:07:01.000Z","date":"2026-09-11","kind":"grant","planned":false,"acquired":true,"shares":3587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."}],"balance_after":24583,"source":{"system":"sec-edgar","filing":"0001894425-26-000020","document":"wk-form4_1789506418.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894425/000189442526000020/wk-form4_1789506418.xml","form_type":"4"}},{"id":696278,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T21:35:50.000Z","date":"2026-08-04","kind":"gift","planned":false,"acquired":false,"shares":2409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a gift/charitable contribution effective August 4, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares."}],"balance_after":20996,"source":{"system":"sec-edgar","filing":"0001894425-26-000018","document":"wk-form4_1785965748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000018/wk-form4_1785965748.xml","form_type":"4"}},{"id":741917,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:02:48.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":30000,"derivative":{"exercise_price":3.43,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-26-072922","document":"tm2617547-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894425/000110465926072922/tm2617547-4_4seq1.xml","form_type":"4"}},{"id":745350,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-09T21:34:43.000Z","date":"2026-06-05","kind":"gift","planned":false,"acquired":false,"shares":2441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a gift/charitable contribution effective June 5, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares."}],"balance_after":23405,"source":{"system":"sec-edgar","filing":"0001894425-26-000014","document":"wk-form4_1781040880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000014/wk-form4_1781040880.xml","form_type":"4"}},{"id":755919,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-06-02T22:08:16.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested\nand exercisable each month thereafter."}],"balance_after":13268,"derivative":{"exercise_price":84.74,"expiration_date":"2031-11-29","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001894425-26-000012","document":"wk-form4_1780438094.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000012/wk-form4_1780438094.xml","form_type":"4"}},{"id":755918,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-02T22:08:16.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":11000,"price":160.2464,"value":1762710.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.66. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25846,"source":{"system":"sec-edgar","filing":"0001894425-26-000012","document":"wk-form4_1780438094.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000012/wk-form4_1780438094.xml","form_type":"4"}},{"id":755917,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-02T22:08:16.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":11000,"price":84.74,"value":932140.0,"ownership":{"direct":true},"balance_after":36846,"source":{"system":"sec-edgar","filing":"0001894425-26-000012","document":"wk-form4_1780438094.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000012/wk-form4_1780438094.xml","form_type":"4"}},{"id":759338,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2026-05-29T22:09:43.000Z","date":"2026-05-27","kind":"exercise","planned":true,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter."}],"balance_after":24268,"derivative":{"exercise_price":84.74,"expiration_date":"2031-11-29","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001894425-26-000010","document":"wk-form4_1780092580.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000010/wk-form4_1780092580.xml","form_type":"4"}},{"id":759337,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-29T22:09:43.000Z","date":"2026-05-27","kind":"sale","planned":true,"acquired":false,"shares":11000,"price":155.5332,"value":1710865.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $154.47 to $156.74. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":25846,"source":{"system":"sec-edgar","filing":"0001894425-26-000010","document":"wk-form4_1780092580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000010/wk-form4_1780092580.xml","form_type":"4"}},{"id":759336,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-05-29T22:09:43.000Z","date":"2026-05-27","kind":"exercise","planned":true,"acquired":true,"shares":11000,"price":84.74,"value":932140.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":36846,"source":{"system":"sec-edgar","filing":"0001894425-26-000010","document":"wk-form4_1780092580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000010/wk-form4_1780092580.xml","form_type":"4"}},{"id":888999,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-24T00:12:20.000Z","date":"2026-02-20","kind":"gift","planned":false,"acquired":false,"shares":3110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a gift/charitable contribution effective February 20, 2026. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares."}],"balance_after":25670,"source":{"system":"sec-edgar","filing":"0001894425-26-000007","document":"wk-form4_1771891938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000007/wk-form4_1771891938.xml","form_type":"4"}},{"id":902304,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":9669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030."}],"balance_after":9669,"derivative":{"underlying":"Common Stock","underlying_shares":9669},"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902303,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":55119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":55119,"derivative":{"exercise_price":124.12,"expiration_date":"2036-02-13","underlying":"Common Stock","underlying_shares":55119},"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902302,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, vested as to 2,717 shares on February 13, 2026, and will vest as to 2,717 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, vested as to 2,717 shares on February 13, 2026, and will vest as to 2,717 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":2717,"derivative":{"underlying":"Common Stock","underlying_shares":2717},"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902301,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, vested as to 2,690 shares on February 13, 2026, and will vest as to 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, vested as to 2,690 shares on February 13, 2026, and will vest as to 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":5380,"derivative":{"underlying":"Common Stock","underlying_shares":2690},"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902300,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":false,"shares":2560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,560 shares on February 12, 2026, and will vest as to 2,560 shares on February 12, 2027, 2,560 shares on February 12, 2028, and 2,560 shares on February 12, 2029, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,560 shares on February 12, 2026, and will vest as to 2,560 shares on February 12, 2027, 2,560 shares on February 12, 2028, and 2,560 shares on February 12, 2029, subject to the terms and conditions of the award."}],"balance_after":7681,"derivative":{"underlying":"Common Stock","underlying_shares":2560},"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902299,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":10755,"price":124.12,"value":1334910.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":28780,"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902298,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-13","kind":"grant","planned":false,"acquired":true,"shares":19935,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award."}],"balance_after":39535,"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902297,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1466,"price":124.12,"value":181959.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":19600,"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902296,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":2717,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":21066,"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902295,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":1452,"price":124.12,"value":180222.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":18349,"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902294,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-13","kind":"exercise","planned":false,"acquired":true,"shares":2690,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19801,"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902293,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":1426,"price":123.1,"value":175540.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\") or performance restricted stock units (\"PRSUs\"), as applicable. No shares were sold."}],"balance_after":17111,"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":902292,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-17T22:47:22.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":true,"shares":2560,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18537,"source":{"system":"sec-edgar","filing":"0001894425-26-000005","document":"wk-form4_1771368439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000005/wk-form4_1771368439.xml","form_type":"4"}},{"id":922908,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-03T23:01:14.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":false,"shares":238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and vested as to 238 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and vested as to 238 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":238},"source":{"system":"sec-edgar","filing":"0001894425-26-000003","document":"wk-form4_1770159672.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000003/wk-form4_1770159672.xml","form_type":"4"}},{"id":922907,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-03T23:01:14.000Z","date":"2026-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":142,"price":136.06,"value":19320.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the \"Company\" or \"Issuer\") to satisfy tax withholding requirements on vesting of restricted stock units (\"RSUs\"). No shares were sold."}],"balance_after":15977,"source":{"system":"sec-edgar","filing":"0001894425-26-000003","document":"wk-form4_1770159672.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000003/wk-form4_1770159672.xml","form_type":"4"}},{"id":922906,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-03T23:01:14.000Z","date":"2026-01-31","kind":"exercise","planned":false,"acquired":true,"shares":238,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16119,"source":{"system":"sec-edgar","filing":"0001894425-26-000003","document":"wk-form4_1770159672.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442526000003/wk-form4_1770159672.xml","form_type":"4"}},{"id":984206,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-12-02T22:14:58.000Z","date":"2025-11-29","kind":"exercise","planned":false,"acquired":false,"shares":4426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on\nNovember 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on\nNovember 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4426},"source":{"system":"sec-edgar","filing":"0001894425-25-000010","document":"wk-form4_1764713695.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442525000010/wk-form4_1764713695.xml","form_type":"4"}},{"id":984205,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-02T22:14:58.000Z","date":"2025-11-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":2248,"price":152.16,"value":342055.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by Neurocrine Biosciences, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold."}],"balance_after":15881,"source":{"system":"sec-edgar","filing":"0001894425-25-000010","document":"wk-form4_1764713695.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442525000010/wk-form4_1764713695.xml","form_type":"4"}},{"id":984204,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-02T22:14:58.000Z","date":"2025-11-29","kind":"exercise","planned":false,"acquired":true,"shares":4426,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18129,"source":{"system":"sec-edgar","filing":"0001894425-25-000010","document":"wk-form4_1764713695.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442525000010/wk-form4_1764713695.xml","form_type":"4"}},{"id":1048677,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-09-04T21:28:48.000Z","date":"2025-09-03","kind":"gift","planned":false,"acquired":false,"shares":1470,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a gift/charitable contribution effective September 3, 2025. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares."}],"balance_after":13703,"source":{"system":"sec-edgar","filing":"0001894425-25-000005","document":"wk-form4_1757021325.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000189442525000005/wk-form4_1757021325.xml","form_type":"4"}},{"id":1072647,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-08-07T20:29:30.000Z","date":"2025-08-05","kind":"gift","planned":false,"acquired":false,"shares":3116,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a gift/charitable contribution effective August 5, 2025. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares."}],"balance_after":15173,"source":{"system":"sec-edgar","filing":"0000914475-25-000164","document":"wk-form4_1754598566.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000164/wk-form4_1754598566.xml","form_type":"4"}},{"id":1088946,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2025-07-11T21:01:03.000Z","date":"2025-07-09","kind":"exercise","planned":true,"acquired":false,"shares":59819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":35268,"derivative":{"exercise_price":84.74,"expiration_date":"2031-11-29","underlying":"Common Stock","underlying_shares":59819},"source":{"system":"sec-edgar","filing":"0000914475-25-000151","document":"wk-form4_1752267655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000151/wk-form4_1752267655.xml","form_type":"4"}},{"id":1088945,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-11T21:01:03.000Z","date":"2025-07-09","kind":"sale","planned":true,"acquired":false,"shares":59819,"price":130.455,"value":7803687.645,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024. Additionally, Issuer\npolicy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.00 to $131.45. The Reporting Person has provided to the issuer, and will\nprovide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":18289,"source":{"system":"sec-edgar","filing":"0000914475-25-000151","document":"wk-form4_1752267655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000151/wk-form4_1752267655.xml","form_type":"4"}},{"id":1088944,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-11T21:01:03.000Z","date":"2025-07-09","kind":"exercise","planned":true,"acquired":true,"shares":59819,"price":84.74,"value":5069062.06,"ownership":{"direct":true},"balance_after":78108,"source":{"system":"sec-edgar","filing":"0000914475-25-000151","document":"wk-form4_1752267655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000151/wk-form4_1752267655.xml","form_type":"4"}},{"id":1091552,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2025-07-07T20:10:27.000Z","date":"2025-07-02","kind":"exercise","planned":true,"acquired":false,"shares":20362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.  These options will expire ten years from the date of grant on November 29, 2031."}],"balance_after":95087,"derivative":{"exercise_price":84.74,"expiration_date":"2031-11-29","underlying":"Common Stock","underlying_shares":20362},"source":{"system":"sec-edgar","filing":"0000914475-25-000149","document":"wk-form4_1751919019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000149/wk-form4_1751919019.xml","form_type":"4"}},{"id":1091551,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-07T20:10:27.000Z","date":"2025-07-02","kind":"sale","planned":true,"acquired":false,"shares":20362,"price":130.1315,"value":2649737.603,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.40. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 200 shares purchased on February 28, 2025, from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":18289,"source":{"system":"sec-edgar","filing":"0000914475-25-000149","document":"wk-form4_1751919019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000149/wk-form4_1751919019.xml","form_type":"4"}},{"id":1091550,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-07T20:10:27.000Z","date":"2025-07-02","kind":"exercise","planned":true,"acquired":true,"shares":20362,"price":84.74,"value":1725475.88,"ownership":{"direct":true},"balance_after":38651,"source":{"system":"sec-edgar","filing":"0000914475-25-000149","document":"wk-form4_1751919019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000149/wk-form4_1751919019.xml","form_type":"4"}},{"id":1123165,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T01:04:35.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":24000,"derivative":{"exercise_price":3.28,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001104659-25-056565","document":"tm2517191-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894425/000110465925056565/tm2517191-6_4seq1.xml","form_type":"4"}},{"id":1268327,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:35:09.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":2690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, and will vest as to 2,690 shares on February 13, 2026, 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"This RSU was granted to the Reporting Person on February 13, 2024.  In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, and will vest as to 2,690 shares on February 13, 2026, 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award."}],"balance_after":8070,"derivative":{"underlying":"Common Stock","underlying_shares":2690},"source":{"system":"sec-edgar","filing":"0000914475-25-000067","document":"wk-form4_1739576102.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000067/wk-form4_1739576102.xml","form_type":"4"}},{"id":1268326,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:35:09.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":2717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, and will vest as to 2,717 shares on February 13, 2026, and 2,717 shares on February 13, 2027, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"This RSU was granted to the Reporting Person on February 13, 2023.  In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, and will vest as to 2,717 shares on February 13, 2026, and 2,717 shares on February 13, 2027, subject to the terms and conditions of the award."}],"balance_after":5434,"derivative":{"underlying":"Common Stock","underlying_shares":2717},"source":{"system":"sec-edgar","filing":"0000914475-25-000067","document":"wk-form4_1739576102.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000067/wk-form4_1739576102.xml","form_type":"4"}},{"id":1268325,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-14T23:35:09.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":10241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029."}],"balance_after":10241,"derivative":{"underlying":"Common Stock","underlying_shares":10241},"source":{"system":"sec-edgar","filing":"0000914475-25-000067","document":"wk-form4_1739576102.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000067/wk-form4_1739576102.xml","form_type":"4"}},{"id":1268324,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2025-02-14T23:35:09.000Z","date":"2025-02-12","kind":"grant","planned":true,"acquired":true,"shares":54645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":54645,"derivative":{"exercise_price":117.18,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":54645},"source":{"system":"sec-edgar","filing":"0000914475-25-000067","document":"wk-form4_1739576102.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000067/wk-form4_1739576102.xml","form_type":"4"}},{"id":1268323,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:35:09.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":1447,"price":116.7471,"value":168933.0537,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":18089,"source":{"system":"sec-edgar","filing":"0000914475-25-000067","document":"wk-form4_1739576102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000067/wk-form4_1739576102.xml","form_type":"4"}},{"id":1268322,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:35:09.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":2690,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19536,"source":{"system":"sec-edgar","filing":"0000914475-25-000067","document":"wk-form4_1739576102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000067/wk-form4_1739576102.xml","form_type":"4"}},{"id":1268321,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:35:09.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":1432,"price":116.8335,"value":167305.572,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":16846,"source":{"system":"sec-edgar","filing":"0000914475-25-000067","document":"wk-form4_1739576102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000067/wk-form4_1739576102.xml","form_type":"4"}},{"id":1268320,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-14T23:35:09.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":2717,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18278,"source":{"system":"sec-edgar","filing":"0000914475-25-000067","document":"wk-form4_1739576102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000067/wk-form4_1739576102.xml","form_type":"4"}},{"id":1285992,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-04T22:51:04.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":false,"shares":238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and will vest as to 238 shares on January 31, 2026, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and will vest as to 238 shares on January 31, 2026, subject to the terms and conditions of the award."}],"balance_after":238,"derivative":{"underlying":"Common Stock","underlying_shares":238},"source":{"system":"sec-edgar","filing":"0000914475-25-000027","document":"wk-form4_1738709457.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000027/wk-form4_1738709457.xml","form_type":"4"}},{"id":1285991,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:51:04.000Z","date":"2025-01-31","kind":"sale","planned":true,"acquired":false,"shares":126,"price":152.9681,"value":19273.9806,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.99 to $154.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":15561,"source":{"system":"sec-edgar","filing":"0000914475-25-000027","document":"wk-form4_1738709457.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000027/wk-form4_1738709457.xml","form_type":"4"}},{"id":1285990,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:51:04.000Z","date":"2025-01-31","kind":"exercise","planned":true,"acquired":true,"shares":238,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15687,"source":{"system":"sec-edgar","filing":"0000914475-25-000027","document":"wk-form4_1738709457.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000027/wk-form4_1738709457.xml","form_type":"4"}},{"id":1345983,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-12-03T23:52:58.000Z","date":"2024-11-29","kind":"exercise","planned":true,"acquired":false,"shares":4426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and will vest as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and will vest as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award."}],"balance_after":4426,"derivative":{"underlying":"Common Stock","underlying_shares":4426},"source":{"system":"sec-edgar","filing":"0000914475-24-000222","document":"wk-form4_1733269971.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000222/wk-form4_1733269971.xml","form_type":"4"}},{"id":1345982,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-03T23:52:58.000Z","date":"2024-11-29","kind":"sale","planned":true,"acquired":false,"shares":2331,"price":126.286,"value":294372.666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.42 to $127.04. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 226 shares purchased on February 29, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":15449,"source":{"system":"sec-edgar","filing":"0000914475-24-000222","document":"wk-form4_1733269971.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000222/wk-form4_1733269971.xml","form_type":"4"}},{"id":1345981,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-12-03T23:52:58.000Z","date":"2024-11-29","kind":"exercise","planned":true,"acquired":true,"shares":4426,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17780,"source":{"system":"sec-edgar","filing":"0000914475-24-000222","document":"wk-form4_1733269971.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000222/wk-form4_1733269971.xml","form_type":"4"}},{"id":1487168,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:20:15.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":24000,"derivative":{"exercise_price":8.7,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001104659-24-069664","document":"tm2416702-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894425/000110465924069664/tm2416702-6_4seq1.xml","form_type":"4"}},{"id":1641735,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-02-15T22:48:20.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":10760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028."}],"balance_after":10760,"derivative":{"underlying":"Common Stock","underlying_shares":10760},"source":{"system":"sec-edgar","filing":"0000914475-24-000075","document":"wk-form4_1708037291.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000075/wk-form4_1708037291.xml","form_type":"4"}},{"id":1641734,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2024-02-15T22:48:20.000Z","date":"2024-02-13","kind":"grant","planned":true,"acquired":true,"shares":54069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":54069,"derivative":{"exercise_price":133.84,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":54069},"source":{"system":"sec-edgar","filing":"0000914475-24-000075","document":"wk-form4_1708037291.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000075/wk-form4_1708037291.xml","form_type":"4"}},{"id":1641733,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-02-15T22:48:20.000Z","date":"2024-02-13","kind":"sale","planned":true,"acquired":false,"shares":1432,"price":132.9407,"value":190371.0824,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,432 shares of common stock issued upon vesting of 2,717 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,285) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $133.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":13128,"source":{"system":"sec-edgar","filing":"0000914475-24-000075","document":"wk-form4_1708037291.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000075/wk-form4_1708037291.xml","form_type":"4"}},{"id":1662751,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-02-03T00:26:29.000Z","date":"2024-01-31","kind":"sale","planned":true,"acquired":false,"shares":126,"price":141.94,"value":17884.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 126 shares of common stock issued upon vesting of 237 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (111) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":11843,"source":{"system":"sec-edgar","filing":"0000914475-24-000030","document":"wk-form4_1706919980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000030/wk-form4_1706919980.xml","form_type":"4"}},{"id":1725956,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-01T22:41:34.000Z","date":"2023-11-29","kind":"sale","planned":true,"acquired":false,"shares":2331,"price":113.5705,"value":264732.8355,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,331 shares of common stock issued upon vesting of 4,425 restricted stock units on November 29, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,094) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $113.17 to $113.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":11732,"source":{"system":"sec-edgar","filing":"0001209191-23-057097","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123057097/doc4.xml","form_type":"4"}},{"id":1799016,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-08-24T00:10:56.000Z","date":"2023-08-21","kind":"sale","planned":true,"acquired":false,"shares":3198,"price":107.3696,"value":343367.9808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 3,198 shares of common stock issued upon vesting of 6,075 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,877) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.05 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes an aggregate of 236 shares purchased on February 28, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":9638,"source":{"system":"sec-edgar","filing":"0001209191-23-047139","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123047139/doc4.xml","form_type":"4"}},{"id":1864172,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-07T20:39:12.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":22000,"derivative":{"exercise_price":12.57,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-23-068927","document":"tm2317994-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894425/000110465923068927/tm2317994-6_4seq1.xml","form_type":"4"}},{"id":1990665,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T22:19:12.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date. The option vests over four years, with 1/16th of the shares of common stock underlying the option vesting upon the three-month anniversary of the Vesting Commencement Date and an additional 1/16th of the shares of common stock underlying the option vesting at the end of each successive three-month period thereafter, subject to the Reporting Person's continued service as a director."}],"balance_after":44000,"derivative":{"exercise_price":6.92,"expiration_date":"2033-02-23","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001104659-23-026111","document":"tm237906-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894425/000110465923026111/tm237906-2_4seq1.xml","form_type":"4"}},{"id":2014207,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-02-16T00:14:24.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":10868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027."}],"balance_after":10868,"derivative":{"underlying":"Common Stock","underlying_shares":10868},"source":{"system":"sec-edgar","filing":"0001209191-23-009888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009888/doc4.xml","form_type":"4"}},{"id":2014206,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2023-02-16T00:14:24.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":67541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":67541,"derivative":{"exercise_price":103.52,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":67541},"source":{"system":"sec-edgar","filing":"0001209191-23-009888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123009888/doc4.xml","form_type":"4"}},{"id":2027007,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-09T00:38:05.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":4508,"price":102.2995,"value":461166.146,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 4,508 shares of common stock issued upon vesting of 8,556 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (4,048) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.10 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":6525,"source":{"system":"sec-edgar","filing":"0001209191-23-007915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123007915/doc4.xml","form_type":"4"}},{"id":2037157,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-02T22:26:28.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":126,"price":108.48,"value":13668.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 126 shares of common stock issued upon vesting of 237 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (111) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":2477,"source":{"system":"sec-edgar","filing":"0001209191-23-006281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919123006281/doc4.xml","form_type":"4"}},{"id":2100473,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-01T23:35:56.000Z","date":"2022-11-29","kind":"sale","acquired":false,"shares":2331,"price":121.9048,"value":284160.0888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,331 shares of common stock issued upon vesting of 4,425 restricted stock units on November 29, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,094) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $121.18 to $122.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 272 shares purchased on August 31, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan."}],"balance_after":2366,"source":{"system":"sec-edgar","filing":"0001209191-22-059242","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122059242/doc4.xml","form_type":"4"}},{"id":2417561,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-02-03T00:58:36.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026."}],"balance_after":950,"derivative":{"underlying":"Common Stock","underlying_shares":950},"source":{"system":"sec-edgar","filing":"0001209191-22-006584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006584/doc4.xml","form_type":"4"}},{"id":2417560,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2022-02-03T00:58:36.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":6464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":6464,"derivative":{"exercise_price":79.02,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":6464},"source":{"system":"sec-edgar","filing":"0001209191-22-006584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919122006584/doc4.xml","form_type":"4"}},{"id":2491151,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-12-02T01:02:14.000Z","date":"2021-11-29","kind":"grant","acquired":true,"shares":17702,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units will vest annually at 25% of the units vesting on each of November 29, 2022, November 29, 2023, November 29, 2024, and November 29, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units will vest annually at 25% of the units vesting on each of November 29, 2022, November 29, 2023, November 29, 2024, and November 29, 2025."}],"balance_after":17702,"derivative":{"underlying":"Common Stock","underlying_shares":17702},"source":{"system":"sec-edgar","filing":"0001209191-21-067375","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121067375/doc4.xml","form_type":"4"}},{"id":2491150,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":26384,"kind":"person","name":"Onyia Jude","position":1,"cik":"0001894425","reported_name":"Onyia Jude","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option","published_at":"2021-12-02T01:02:14.000Z","date":"2021-11-29","kind":"grant","acquired":true,"shares":120169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":120169,"derivative":{"exercise_price":84.74,"expiration_date":"2031-11-29","underlying":"Common Stock","underlying_shares":120169},"source":{"system":"sec-edgar","filing":"0001209191-21-067375","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121067375/doc4.xml","form_type":"4"}}]}